The FDA slaps wrists and takes names, Farxiga expands FDA approval, BioVie makes cash-light acquisition, Pfizer targets fungus, and one IPO down, another to go.

Sponsors
https://www.thescopemethod.com

Story References
https://tinyurl.com/Niche-047-1
https://tinyurl.com/Niche-047-2
https://tinyurl.com/Niche-047-3
https://tinyurl.com/Niche-047-4
https://tinyurl.com/Niche-047-5
https://tinyurl.com/Niche-047-6

Music by Luke Goodson
https://www.soundcloud.com/lukegoodson

The Niche Podcast brings you interviews with industry experts and top stories from last week in biotech, pharma, clinical research, and the life science industries. You can expect highlights about new technologies, biotech and pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to IPOs. The Niche also tries to highlight trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed, move through clinical trials, and become approved by regulatory agencies. It’s news, with a dash of perspective, focused on these Niche industries.